Chemed CorpCHE

Chemed Corp, the healthcare services group behind VITAS hospice care, reported $657.5 million in revenue for the quarter ending 31 March 2026, with net income attributable to parent climbing to $66.3 million and diluted earnings per share at $4.84. Operating income clocked in at $84.6 million, while operating cash flow hit $88.2 million, a figure that looks impressive until you notice the company’s cash and equivalents sat at just $16.9 million at quarter-end. The cash conversion story is the first thing that stalls in any hospice provider’s narrative, and Chemed’s filings put the spotlight on working capital discipline rather than balance-sheet extravagance.

The company’s services are delivered through a mix of company-owned branches, independent contractors, and franchisees, a structure that spreads risk but also fragments control. Chemed’s 10-Q notes that none of its hospice programs exceeded inpatient payment limits during the three months ended March 2026 or March 2025, a detail that speaks to regulatory tightrope-walking rather than customer growth. The same filing adds that unsatisfied performance obligations-chiefly bereavement support-run for at least twelve months after discharge, a promise that sounds humane until you ask who funds the float.

Assets stood at $1.54 billion against liabilities of $687.8 million, leaving stockholders’ equity at $848.0 million. Capex for the quarter was $17.1 million, while inventory dipped by $335,000 to $7.2 million, a rounding error in a $1.5 billion balance sheet but a useful reminder that hospice is not a business that lives on shelves. The company’s diluted share count sat at 13.7 million shares, a figure that matters because repurchase programmes are disclosed in 10b5-1 filings that read like a management desks’s attempt to schedule its own probity.

The next filing page to watch is the 11-K for 2025, which shows employee contribution limits set at 85% of included compensation or the IRC maximum, whichever is lower. That is not a revenue line, but it is a window into how Chemed structures incentives for its people in a sector where morale and reimbursement rates move in lockstep. Meanwhile, the SEC submissions JSON for Chemed lists the usual parade of Forms 10-Q, 10-K, 8-K, and Section 16 filings, a bureaucratic reality that feels distant from the bedside promises made in marketing brochures.

The company’s cash position remains the central tension: strong operating cash flow, weak closing cash balance, and a balance sheet that looks robust but is not liquid enough to fund a multi-month revenue lull. The hospice sector’s unit economics reward scale and compliance discipline; Chemed’s filings show it has the former, but the latter is the real constraint.

Chemed’s shares trade on the NYSE under the ticker CHE, a label so plain it feels like a deliberate refusal to dress up mortality as a growth story. The trading view is available from any major terminal, but the chart itself is less interesting than the footnote that says liquidity is fine but not flush. That is the hospice business in one snapshot: you can see the chart, but the story is in the small print.

The company’s franchise model and contractor network mean customer concentration is diffuse, but counterparty concentration is real. If a large franchisee or contractor stumbles, the revenue recognition and cash collection timelines can stretch faster than a hospice nurse’s patience. The 10-Q’s disclosure on inpatient payment limits is a regulatory comfort blanket, not a customer growth story. Growth in this sector is not about selling more product; it is about keeping reimbursement rates stable and avoiding citations. Chemed’s filings show it has managed that so far, but the cash buffer is thin enough that a single quarter of billing delays could make the balance sheet feel less sturdy.